Axiom Investment Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Axiom Investment Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$252K	Sell	507 -126	-20%	-$55.8K	0.17%	103
2026 Q1	$283K	Buy	+633	New	+$295K	0.22%	86
2022 Q4	–	Sell	-108	Closed	-$30K	–	422
2022 Q3	$30K	Buy	+108	New	+$31.1K	0.06%	201
2021 Q2	–	Sell	-173	Closed	-$36K	–	202
2021 Q1	$36K	Buy	+173	New	+$38K	0.03%	164
2019 Q3	–	Sell	-1,373	Closed	-$251K	–	414
2019 Q2	$251K	Buy	+1,373	New	+$240K	0.05%	318

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Axiom Investment Management's VRTX Position: Q2 2026 in Review

Axiom Investment Management reduced its Vertex Pharmaceuticals (VRTX) stake by 20% in Q2 2026, selling an estimated $55.8K and leaving 507 shares worth $252K. The position accounts for 0.17% of the portfolio, ranked #103.

Axiom Investment Management first reported a position in VRTX in Q2 2019 and has held it in 5 quarters since. The position peaked at $283K in Q1 2026. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Axiom Investment Management held 507 shares of Vertex Pharmaceuticals worth $252K as of Q2 2026.
Axiom Investment Management sold 126 Vertex Pharmaceuticals shares in Q2 2026, an estimated $55.8K.
Vertex Pharmaceuticals made up 0.17% of Axiom Investment Management's portfolio in Q2 2026, its #103 holding.
Axiom Investment Management first reported a position in Vertex Pharmaceuticals in Q2 2019 and has held it in 5 quarters since.
Axiom Investment Management's Vertex Pharmaceuticals position peaked at $283K in Q1 2026.
1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Axiom Investment Management's 13F filing for Q2 2026, filed 31 Jul 2026.